A new CBD prescription medication is currently in clinical trials that plan to be completed by June, with hopes of making the product widely available for pharmaceutical use by mid next year. The product being developed is a CBD gel called Zygel. The medication is aimed at helping children and teenagers who suffer from Fragile X syndrome.
Fragile X syndrome is rare but affects children’s intellectual abilities and causes development problems. Research has found that children who suffer from the effects of this lowered nerve cell communication may actually have abnormalities in their endocannabinoid system. For this reason, CBD has been proposed as a solution because of its ability to support the body’s endocannabinoid system. Zygel is applied on the skin of the shoulder or upper arm and delivers CBD to the bloodstream. Hopefully the trial results will show an improvement in the patients’ symptoms so that Zygel can be approved for pharmaceutical use.
Read more here:https://fragilexnewstoday.com/2020/05/19/top-line-results-of-connect-fx-trial-zygel-cbd-gel-treatment-likely-by-mid-year/